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The aim of this study was to develop and validate a clinical and trans-plant-specific prognostic score using data from a large cohort ofpatients with myelodysplastic syndromes reported to the European
Society for Blood and Marrow Transplantation registry. A Cox model was
fitted to detect clinical and transplant-related variables prognostic of out-
come. Then, cross-validation was performed to evaluate the validity and
consistency of the model. Seven independent risk factors for survival were
identified: age ≥50 years, matched unrelated donor, Karnofsky Performance
Status <90%, very poor cytogenetics or monosomal karyotype, positive
cytomegalovirus status of the recipient, blood blasts >1%, and platelet
count ≤50 x 109/L prior to transplantation. Incorporating these factors into
a four-level risk score yielded hazard ratios for death, with low-risk (score
of 0-1) as reference, of 2.02 (95% CI: 1.41-2.90) for the intermediate-risk
group (score of 2-3), 3.49 (95% CI: 2.45-4.97) for the high-risk group (score
of 4-5), and 5.90 (95% CI: 4.01-8.67) for the very high-risk group (score of
>5). The score was predictive of survival, relapse-free survival, relapse, and
non-relapse mortality (P<0.001, respectively). Cross-validation yielded sig-
nificant and reproducible improvement in prognostic ability with C-statis-
tics being 0.609 (95% CI: 0.588-0.629) versus 0.555 for the Gruppo Italiano
Trapianto di Midollo Osseo registry and 0.579 for the Center for Blood and
Marrow Transplant Research registry. Prediction was even further aug-
mented after applying a nomogram using age and platelets as continuous
variables showing C-statistics of 0.628 (95% CI: 0.616-0.637). In conclu-
sion, compared to existing prognostic systems, this proposed transplant-
specific risk score offers improved performance with respect to post-trans-
plant risk stratification in myelodysplastic syndromes. 
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Myelodysplastic syndromes (MDS) are a heteroge-
neous group of clonal hematopoietic disorders that are
characterized by abnormal cellular maturation resulting
in cytopenia and a variable risk of progression to acute
leukemia.1 Allogeneic stem-cell transplantation is still the
only curative treatment option.2-4 In order to recommend
MDS patients for transplantation besides considering
only disease-specific factors, such as those proposed by
the International Prognostic Scoring System (IPSS) and its
revision (IPSS-R),5,6 a valid and readily reproducible trans-
plant-specific scoring system is needed.7,8
Recently, two groups have developed prognostic sys-
tems incorporating patient-specific as well as transplant-
specific factors. The Gruppo Italiano Trapianto di Midollo
Osseo (GITMO) registry developed a transplantation risk
index consisting of the following factors: age (<50 or ≥50
years), IPSS-R score (low, intermediate, high, or very
high), monosomal karyotype (yes or no), refractoriness to
chemotherapy (yes or no), and Hematopoietic Cell
Transplantatiom Comorbidity Index score (HCT-CI).9
The resulting risk index could clearly distinguish four dif-
ferent groups (low, intermediate, high, and very high)
with corresponding overall survival rates at 5 years of
76%, 48%, 18%, and 5%. The other prognostic score, by
the Center for Blood and Marrow Transplant Research
(CIBMTR) registry, included the following criteria: age
(18-29, 30-49, or ≥50 years), Karnofsky status (90-100 or
<90%), cytogenetics (very good to intermediate, poor,
very poor or monosomal karyotype), blood blasts before
transplantation (>3 or ≤3%) and platelet count before
transplantation (>50 or ≤50 x 109/L). This system also dis-
criminated four risk groups (low, intermediate, high, and
very high) and showed corresponding overall survival
rates at 3 years of 71%, 49%, 41%, and 25%.10 Both sys-
tems resulted in relevant re-classification of patients in
comparison with the IPSS-R while providing only modest
improvement in predictability. While neither score has
been externally validated nor investigated regarding prog-
nostic power in large and independent cohorts, we
hypothesized that both scores not only vary in design
and follow-up but would also vary in prognostic ability
when applied to the same cohort.7,8
We, therefore, aimed to develop and validate a clinical
and transplant-specific prognostic score using data from a
large cohort of MDS patients reported to the European
Society for Blood and Marrow Transplantation (EBMT)
registry and to validate and compare currently existing




The EBMT is a voluntary organization that comprises more
than 500 transplant centers, mainly from Europe. Membership
requires submission of the minimal essential data form A for all
consecutive patients to a central registry from which patients
can be identified by diagnosis of underlying disease and type of
transplantation. The information in the minimal essential data
form A data is updated annually. Informed consent to transplan-
tation was obtained and data were collected locally according to
regulations that were applicable at the time of transplantation.
All transplantation centers were required to obtain written
informed consent before data registration with the EBMT in
accordance with the 1975 Helsinki Declaration.
Patients
Adult patients (≥18 years) with MDS who underwent trans-
plantation from an HLA-identical sibling or matched unrelated
donor between 2000 to 2014 were included. Patients were eligi-
ble if there was full information on their: diagnosis, donor data,
cytogenetic risk, platelet count and blood blasts at transplanta-
tion. Cytogenetic risk was stratified based on previously estab-
lished systems.6,11 The prognostic subgroups were the following:
del(11q) and -Y (very good); del(5q), del(12p), del(20q), and nor-
mal karyotype (good); del(7q), +8, i(17q), +19, and other inde-
pendent clones (intermediate); complex karyotype (three abnor-
malities), inv(3), del(3q), and translocations involving 3q (poor),
and very complex karyotype with more than three abnormali-
ties (very poor). Monosomal karyotype was defined as mono-
somy of two or more chromosomes or one single autosomal
monosomy in the presence of other structural abnormalities.12
The IPSS-R was calculated prior to transplantation. In total, 1059
patients met the criteria and were included in the EBMT cohort.
To evaluate possible selection bias, outcomes were compared
between the final cohort and remaining patients not included in
the analysis due to missing data in the registry (n=5122). Within
the EBMT cohort, 519 and 876 patients had full data on all fac-
tors included in either the GITMO or CIBMTR score. 
Score development
The development of the transplant-specific risk score consist-
ed of two steps. First, a Cox proportional hazards model using
backward and forward selection was used to identify significant
covariates for overall survival.13 Then, the hazard ratios (HR)
obtained were classified as large (HR >1.59), intermediate (1.25<
HR <1.60) and small (HR <1.25). Subsequently, a scoring rule
was defined in which large effects were assigned two points,
intermediate effects were assigned one point and small effects
were assigned zero points. Scores were grouped based on asso-
ciated hazard ratios into low-, intermediate-, high-, and very
high–risk groups, providing group-based risk predictions for
MDS. A second score was developed, based on the β coefficients
derived from the model defined above, to provide individual-
ized/patient-specific risk predictions. Second, both developed
scores were validated and then compared to existing systems by
assessing each score’s prognostic performance. 
Statistical analysis
Overall survival and relapse-free survival were estimated using
the Kaplan-Meier method and compared with the log-rank test in
univariable analysis. Non-relapse mortality and relapse were ana-
lyzed in a competing risks framework by using the cumulative
incidence estimator and the Gray test for univariable analysis.14
Cox proportional hazards regression of complete data was used
to develop the two new scores. Maximum likelihood from the
Cox model was used to establish cutoffs for continuous variables.
Score performance was analyzed using the concordance index
(C): the probability that a patient who experienced an event had
a higher risk score than a patient who did not (C >0.5 suggesting
predictive ability).15,16 Each system was validated using 5-fold
cross-validation with 100 repetitions. P values <0.05 were consid-
ered statistically significant. Analyses were performed using SPSS
for Windows version 24 (SPSS, Chicago, IL, USA) and R package
version 3.4.3 (The R Foundation, Vienna, Austria).
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Results
Patients 
The characteristics of the patients and transplants of the
total EBMT cohort (n=1059) are listed in Table 1. The
median follow-up was 69 months (95% CI: 62-76) and the
5-year overall survival was 38.6% (95% CI: 35.4-41.7)
while the relapse-free survival was 33.5% (95% CI: 30.4-
36.6). 
Transplant-specific risk score
Table 2 summarizes the seven variables identified as
independent predictors of overall survival in the multivari-
able analysis: age ≥50 years, matched unrelated donor,
Karnofsky Performance Status <90%, very poor cytogenet-
ics or monosomal karyotype, positive cytomegalovirus
(CMV) status of the recipient, blood blasts >1%, and
platelet count ≤50 x 109/L at the time of transplantation. A
weighted score of two was assigned to older age (≥50 years)
and very poor cytogenetics or monosomal karyotype,
whereas matched unrelated donor, Karnofsky Performance
Status <90%, positive CMV status of the recipient, blood
blasts >1%, and platelet count ≤50 x 109/L prior to trans-
plantation were assigned a score of one. 
The overall score ranged from zero to nine, with increas-
ing scores indicating higher risk of death. Based on the
score, four risk groups were delineated: low (0-1), interme-
diate (2-3), high (4-5), and very high (>5). The hazard ratio
for death (with the low-risk group as the reference) was
2.02 (95% CI: 1.41-2.90) for the intermediate-risk group,
3.49 (95% CI: 2.45-4.97) for the high-risk group, and 5.90
(95% CI: 4.01-8.67) for the very high–risk group.
Corresponding survival rates were 68.7% for the low-risk
group, 43.2% for the intermediate-risk group, 26.6% for
the high-risk group, and 9.5% for the very high-risk group.
Overall, the EBMT transplant-specific risk score was predic-
tive of overall survival (P<0.001) (Figure 1). 
Secondary endpoints
The EBMT cohort was also used to apply the developed
score to all secondary objectives. The developed score
(overall and in all risk groups) was associated with all sec-
ondary endpoints (P=0.001) (Table 3 and Figure 1B-D).
The 5-year relapse-free survival rate was 68.4% (95% CI:
EBMT transplant-specific risk score for MDS
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Platelets at transplant, x 109/L
≤ 50                                                                                                  382 (38)
> 50                                                                                                  677 (62)
Revised IPSS category
very low                                                                                             32 (3)
low                                                                                                    259 (24)
intermediate                                                                                  317 (32)
high                                                                                                   205 (20)
very high                                                                                            86 (8)
unknown                                                                                          150 (13)
Conditioning intensity
myeloablative                                                                                 336 (32)
reduced                                                                                           620 (58)
non-myeloablative                                                                         103 (10)
Pretreatment
chemotherapy                                                                                235 (22)
hypomethylating agents                                                               214 (20)
both                                                                                                    42 (4)
none                                                                                                 568 (54)
Graft source
bone marrow                                                                                  147 (14)
peripheral blood                                                                           912 (86)
Time to transplant, months
median (range)                                                                         7 (0.2 to 328)
Donor type
HLA-identical sibling                                                                    622 (59)
matched unrelated                                                                       437 (41)
Cytomegalovirus serostatus  of recipient
negative                                                                                           416 (39)
positive                                                                                            614 (58)
unknown                                                                                            29 (3)
Anti-thymocyte globulin                                                                 491 (46)
Ex vivo T-cell depletion                                                                   43 (4)
n: number; IPSS: International Prognosis Scoring System.
continued from the previous coloum
continued in the next coloum
Table 1. Patient and transplantation characteristics of 1059 patients
with myelodysplastic syndromes in the total EBMT cohort.
Characteristics                                                         Total cohort, n (%)
Number of patients                                                                            1059
Age at transplant, years
median (range)                                                                         56 (18 to 73)
Patient’s sex
female                                                                                              446 (42)
male                                                                                                 613 (58)
Secondary disorder
no                                                                                                      776 (74)
yes                                                                                                    201 (19)
unknown                                                                                            92 (7)
Karnofsky index, %
90 to 100                                                                                          630 (60)
< 90                                                                                                  252 (23)
unknown                                                                                          177(17)
Comorbidity index, %
0 to 2                                                                                                 462 (44)
≥ 3                                                                                                     190 (18)
unknown                                                                                          407 (38)
Cytogenetic risk
very good                                                                                           26 (3)
good                                                                                                 132 (13)
intermediate                                                                                  357 (34)
poor                                                                                                  299 (28)
very poor                                                                                           45 (4)
monosomal karyotype                                                                  200 (19)
Marrow blasts at transplant, %
≤ 2                                                                                                     333 (31)
2 to 5                                                                                                 258 (24)
5 to 10                                                                                              170 (16)
> 10                                                                                                  114 (12)
unknown                                                                                          210 (17)
Blood blasts at transplant, %
≤ 1                                                                                                     929 (88)
> 1                                                                                                    130 (12)
58.4-78.4) for the low-risk group, 43.3% (95% CI: 37.2-
49.4) for the intermediate-risk group, 26.0% (95% CI:
20.7-31.3) for the high-risk group, and 11.5% (95% CI:
5.4-17.6) for the very high-risk group (P<0.001) (Figure
2B). The cumulative incidence of relapse and non-relapse
mortality at 5 years according to risk group were, respec-
tively: 16.9% and 12.8% (low-risk group), 28.2% and
27.7% (intermediate-risk group), 36.0% and 36.9% (high-
risk group), and 46.0% and 44.3% (very high-risk group)
(Figure 2C,D).
Nomogram
We aimed to refine the transplant-specific risk score fur-
ther by using age and platelet count at transplantation as
continuous variables while the other variables remained in
their categorical structure. We provide a discrete/continu-
ous nomogram to interpolate the final score and assess an
individual patient’s risk in an easy manner (Figure 2). For
each of the seven prognostic factors, individual points are
assigned, which are subsequently summed to a total point
scale. The final score is then translated into predicted sur-
vival rates at different time points for each patient. For
instance, 55-year old patients presenting with a platelet
count of 150 x 109/L, blasts ≤1%, good cytogenetics, a
Karnofsky Performance Status of 90% who are seroposi-
tive for CMV and for whom an identical sibling donor is
available show estimated survival rates at 3 and 5 years of
57% (95% CI: 51-63) and 47% (95% CI: 41-54), respec-
tively.
Validation of existing systems
The overall score from the CIBMTR ranged from zero
to seven and was used to define four risk categories: low
risk (0-1, n=46), intermediate risk (2-3, n=434), high risk
(4-5, n=365), and very high risk (>5, n=31). The 5-year
overall survival rates were 55.8% (95% CI: 39.9-71.7) for
the low-risk group, 42.3% (95% CI: 37.2-47.4) for the
intermediate-risk group, and 27.2% (95% CI: 21.9-32.5)
for the high-risk group. Rates were not estimable in the
very high-risk group because the median follow-up was
42.6 months in this group while median overall survival
was 11.8 months (95% CI: 3.1-20.4) (Figure 3A). The
GITMO score values ranged from zero to eight. The actu-
al score delineated four risk-groups: low (0-1, n=81), inter-
mediate (2-3, n=200), high (4, n=123), and very high (>4,
n=115). The overall survival rates at 5 years were 62.7%
(95% CI: 51.7-73.7) for the low-risk group, 41.4% (95%
CI: 34.0-48.8) for the intermediate-risk group, 24.1%
(95% CI: 15.1-33.1) for the high-risk group, and 15.8%
(95% CI: 8.2-23.4) for the very high-risk group (Figure 3B).
Overall, both scores could be validated (P<0.001).
Comparison of prognostic systems
Both existing scores from GITMO and CIBMTR were
then compared with the developed EBMT transplant-spe-
cific risk score with respect to their performance regard-
ing overall survival. The CIBMTR and GITMO scores
showed modest performance, with C-statistics after
cross-validation being 0.555 (95% CI: 0.524-0.586) and
0.579 (95% CI: 0.570-0.588), whereas the IPSS-R resulted
in C-statistics of 0.551 (95% CI: 0.530-0.566). The devel-
oped categorized EBMT transplant-specific risk score
showed C-statistics of 0.609 (95% CI: 0.588-0.629) indi-
cating an improvement in prognostic performance, which
was further improved using age and platelet count as con-
tinuous variables as indicated by the C-statistics of 0.628
(95% CI: 0.616-0.637).
Discussion
The major findings of this analysis can be summarized
as follows. First, seven independent risk factors (age, cyto-
genetics, thrombocytopenia and increasing blood blasts at
transplantation, Karnofsky Performance Status, donor
relation, and CMV status of the recipient) could be suc-
cessfully incorporated into a transplant-specific risk score.
Second, this EBMT transplant-specific risk score enabled
significantly improved prediction of outcome in compari-
son with currently existing systems.
The EBMT transplant-specific risk score presented here
considered conventional clinically derived risk factors at
transplantation and can thus be readily calculated. The pri-
mary objective in developing this score was to improve
our ability to predict survival of MDS patients after trans-
plantation; furthermore, the score was predictive of
relapse-free survival, relapse and non-relapse mortality.
Moreover, sub-analyses of all MDS patients in the EBMT
registry (n=6181), of whom 5122 were not included in the
present study because of missing data, revealed a better
overall survival rate at 5 years for excluded patients (48%)
compared with that of the patients used to develop the
score (39%) while non-relapse mortality was 29%, respec-
tively. Most patients had to be excluded because of miss-
ing information regarding cytogenetics. Multiple imputa-
tion of these patients revealed no difference in score per-
formance. Collectively, the prognostic ability could be
improved using the proposed EBMT transplant-specific
N. Gagelmann et al.
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Table 2. Multivariate analysis on overall survival showing seven inde-
pendent risk factors after stepwise selection using a Cox proportional
hazards model.
Factor                                              HR (95% CI)              P            Score 
                                                                                                        value
Age at transplant, years                                                            <0.001
< 50                                                            reference
≥ 50                                                       1.71 (1.39-2.09)                                    2
Blood blasts at transplant, %                                                     0.03
≤ 1                                                              reference
> 1                                                         1.39 (1.03-1.86)                                     1
Platelets at transplant, x109/L                                                   0.001
> 50                                                            reference
≤ 50                                                      1.46 (1.17-1.82)                                     1
Donor type                                                                                   <0.001
HLA-identical sibling                              reference
matched unrelated                            1.39 (1.13-1.71)                                     1
Cytogenetic risk                                                                         <0.001
very good to poor                                   reference
very poor/monosomal karyotype    1.71 (1.43-2.06)                                     2
Cytomegalovirus serostatus
of recipient                                                                                  <0.001
negative                                                     reference
positive                                                 1.39 (1.16-1.65)                                     1
Karnofsky index, %                                                                    <0.001
90 to 100                                                    reference
< 90                                                       1.44 (1.20-1.72)                                     1
HR: hazard ratio; CI: confidence interval.
risk score while C-statistics still showed moderate power;
thus, prognostic systems in MDS may be validated and
updated offering improved risk stratification if more data
become available in the registries in the future.
While another study by the EBMT assessed the prog-
nostic utility of the IPSS-R in patients following transplan-
tation, finding modest applicability of this disease-specific
approach,17 we evaluated two systems that used trans-
plant- and patient-related approaches. The CIBMTR score
showed limited to modest performance (0.555) but result-
ed in an even better prognostic ability (with a concordance
index up to 0.582 after cross-validation) in our cohort than
originally reported (0.575) while the GITMO score
showed better performance (0.579). We acknowledge the
limitation of the lack of information regarding the HCT-CI
in a sufficient number of patients, which could therefore
not be included in the final multivariable model for the
development of the EBMT transplant-specific risk score.
The Karnofsky Performance Status was used instead.
However, the actual performance status of a patient may
vary according to clinicians or at different times during the
transplantation evaluation. Other tools evaluating patient
fitness, including the HCT-CI may be additionally used as
they become available in larger populations.
To investigate to what extent a transplant-specific
approach will be generally feasible, we evaluated the
prognostic power of the IPSS-R resulting in C-statistics of
0.551 (95% CI: 0.530-0.566), confirming that transplant-
specific risk stratification may enable optimized counsel-
ing of patients. However, although the proposed EBMT
EBMT transplant-specific risk score for MDS
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Figure 1. Kaplan-Meier analysis of survival following allogeneic stem cell transplantation in patients with myelodysplastic syndrome stratified according to each




transplant-specific risk score demonstrated improved
prognostic capacity over the IPSS-R, the magnitude of this
benefit was still moderate, suggesting that the combined
use of prognostic systems may provide the most appropri-
ate prognostication, until systems with significantly better
performance become available.
None of the existing scores investigated the possible
impact of CMV on outcome. CMV is an important cause
of morbidity and mortality after allogeneic stem-cell
transplantation.18 During recent years, major advances
have been achieved regarding antiviral prophylactic
strategies, and new sensitive diagnostic techniques have
been developed.19-21 A recent evidence synthesis of the
efficacy and safety of different prophylactic strategies for
CMV highlighted inconclusive results in terms of sur-
vival while CMV disease and infection could be signifi-
cantly reduced using antiviral agents.20 Furthermore, it is
unclear whether different prophylactic agents for graft-
versus-host disease increase the risk for CMV infection or
disease after transplantation. Aggregated evidence did
not show an increased risk for CMV reactivation in ran-
domized trials on antithymocyte globulin, which was
given to 46% of our EBMT cohort, in comparison with
standard prophylaxis using cyclosporine and methotrex-
N. Gagelmann et al.
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Figure 2. Nomogram of the EBMT transplant-specific risk score: for each of the seven prognostic factors. Corresponding points are assigned, which are subsequently
summed to make a total point scale. This final score is then translated into predicted survival rates at different time points for each patient. CMV: cytomegalovirus;
Tx: transplantation; MK: monosomal karyotype; 12m: 12-month; 36m: 36-month; 60m: 60-month.
Table 3. Transplant-specific MDS risk score prediction of relapse-free survival, non-relapse mortality and incidence of relapse.
                                                         Relapse-free survival                                            Non-relapse mortality                          Incidence of relapse
Risk group                      HR (95% CI)                                  P                                   HR (95% CI)                   P                    HR (95% CI)               P
Score overall                                                                                   <0.001                                                                                <0.001                                                        <0.001
low                                         reference                                                                                           reference                                                       reference                      
intermediate                   2.03 (1.38-2.98)                                  <0.001                                    2.08 (1.16-3.75)                   0.01                   1.80 (1.04-3.10)              0.03
high                                   3.47 (2.39-5.06)                                  <0.001                                    2.99 (1.68-5.30)                <0.001                 2.68 (1.57-4.57)           <0.001
very high                          5.77 (3.85-8.66)                                  <0.001                                    4.18 (2.25-7.76)                <0.001                 3.70 (2.09-6.55)           <0.001
HR: hazard ratio; CI: confidence interval.
ate or tacrolimus.22 Further analyses, however, showed
no significant impact of T-cell depletion or the presence
of acute graft-versus-host disease at baseline on outcome
of antiviral prophylaxis in terms of CMV infection, sur-
vival or safety.20 Hence, the CMV serological status of the
transplant recipient still has a strong influence on out-
come.23 In our analysis, a positive CMV serostatus of the
recipient was associated with a 39% increased risk of
death, as well as higher rates of non-relapse mortality.
The significant impact of CMV on outcome in a multi-
variable model in this large cohort of MDS patients sup-
ports further evaluation of antiviral agents, such as leter-
movir, affecting not only CMV infection and disease but
also mortality.20,21
The role of molecular genetics after transplantation has
been investigated recently. Most studies24-26 found a nega-
tive impact on outcome in patients with p53 mutations
while one study26 suggested that p53 as well as RAS-path-
way mutations were mainly seen in patients carrying
complex karyotypes. Although molecular genetics have
not been included in any existing system and were not
available in a suitable number of patients in this analysis,
incorporation of genomic aberrations may refine systems
in the future. 
Regarding conditioning regimens, the introduction of
reduced-intensity conditioning has resulted in a significant
reduction of transplant-related toxicity and mortality.27 Our
analysis, in line with the CIBMTR study, found at least
similar effects of reduced-intensity and myeloablative reg-
imens. As with any retrospective analysis, these results are
prone to bias. Patients perceived as being at greater risk
might have been favorably treated using myeloablative
conditioning. In our study, patients receiving reduced-
intensity conditioning were even older and showed a
worse performance status than patients given myeloabla-
tive conditioning. This observation is supported by a
recent prospective study by the EBMT,28 in which it was
found that the administration of reduced-intensity condi-
tioning before transplantation in MDS patients resulted in
at least an equivalent survival trend for a better overall sur-
vival at 2 years, whereas non-relapse mortality appeared to
be higher after using myeloablative conditioning.
In conclusion, this EBMT transplant-specific risk score
could improve prediction of outcome for MDS patients
undergoing allogeneic stem-cell transplantation. This
readily available score enables optimized clinical decision-
making with respect to allogeneic stem-cell transplanta-
tion in patients with MDS.
EBMT transplant-specific risk score for MDS
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Figure 3. Kaplan-Meier analysis of survival following allogeneic stem-cell transplantation in patients with myelodysplastic syndrome stratified according to their
risk group.  (A) Center for International Blood and Marrow Transplant Research (CIBMTR) registry. (B) Gruppo Italiano Trapianto di Midollo Osseo (GITMO) registry.
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